-
Something wrong with this record ?
Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension
S. Hojná, H. Rauchová, H. Malínská, I. Marková, M. Hüttl, F. Papoušek, M. Behuliak, D. Miklánková, Z. Vaňourková, J. Neckář, M. Kadlecová, P. Kujal, J. Zicha, I. Vaněčková
Language English Country France
Document type Journal Article
- MeSH
- Adiposity drug effects MeSH
- Anti-Inflammatory Agents pharmacology MeSH
- Antihypertensive Agents pharmacology MeSH
- Antioxidants pharmacology MeSH
- Benzhydryl Compounds pharmacology MeSH
- Energy Metabolism drug effects MeSH
- Glucosides pharmacology MeSH
- Weight Loss drug effects MeSH
- Hypertension drug therapy genetics metabolism physiopathology MeSH
- Blood Pressure drug effects MeSH
- Disease Models, Animal MeSH
- Rats, Sprague-Dawley MeSH
- Rats, Transgenic MeSH
- Renin genetics MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
The new antidiabetic drugs, gliflozins, inhibit sodium-glucose transporter-2 in renal proximal tubules promoting glucose and sodium excretion. This leads not only to a significant improvement of glucose control but also to the reduction of blood pressure and body weight in both diabetic patients and experimental models. We examined whether these beneficial effects can also be achieved in a non-diabetic hypertensive model, namely in Ren-2 transgenic rats (TGR). Adult 6-month-old hypertensive TGR and their normotensive controls (Hannover Sprague-Dawley rats), were either untreated or treated with empagliflozin (10 mg/kg/day) for two months. Telemetric blood pressure monitoring, renal parameters as well as cardiac function via echocardiography were analyzed during the experiment. At the end of the study, the contribution of major vasoactive systems to blood pressure maintenance was studied. Metabolic parameters and markers of oxidative stress and inflammation were also analyzed. Empagliflozin had no effect on plasma glucose level but partially reduced blood pressure in TGR. Although food consumption was substantially higher in empagliflozin-treated TGR compared to the untreated animals, their body weight and the amount of epididymal and perirenal fat was decreased. Empagliflozin had no effect on proteinuria, but it decreased plasma urea, attenuated renal oxidative stress and temporarily increased urinary urea excretion. Several metabolic (hepatic triglycerides, non-esterified fatty acids, insulin) and inflammatory (TNF-α, leptin) parameters were also improved by empagliflozin treatment. By contrast, echocardiography did not reveal any effect of empagliflozin on cardiac function. In conclusion, empagliflozin exerted beneficial antihypertensive, anti-inflammatory and metabolic effects also in a non-diabetic hypertensive model.
Department of Cardiology Institute of Physiology Czech Academy of Sciences Prague Czech Republic
Department of Pathology 3rd Faculty of Medicine Charles University Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011774
- 003
- CZ-PrNML
- 005
- 20220506130240.0
- 007
- ta
- 008
- 220425s2021 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biopha.2021.112246 $2 doi
- 035 __
- $a (PubMed)34601191
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Hojná, Silvie $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
- 245 10
- $a Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension / $c S. Hojná, H. Rauchová, H. Malínská, I. Marková, M. Hüttl, F. Papoušek, M. Behuliak, D. Miklánková, Z. Vaňourková, J. Neckář, M. Kadlecová, P. Kujal, J. Zicha, I. Vaněčková
- 520 9_
- $a The new antidiabetic drugs, gliflozins, inhibit sodium-glucose transporter-2 in renal proximal tubules promoting glucose and sodium excretion. This leads not only to a significant improvement of glucose control but also to the reduction of blood pressure and body weight in both diabetic patients and experimental models. We examined whether these beneficial effects can also be achieved in a non-diabetic hypertensive model, namely in Ren-2 transgenic rats (TGR). Adult 6-month-old hypertensive TGR and their normotensive controls (Hannover Sprague-Dawley rats), were either untreated or treated with empagliflozin (10 mg/kg/day) for two months. Telemetric blood pressure monitoring, renal parameters as well as cardiac function via echocardiography were analyzed during the experiment. At the end of the study, the contribution of major vasoactive systems to blood pressure maintenance was studied. Metabolic parameters and markers of oxidative stress and inflammation were also analyzed. Empagliflozin had no effect on plasma glucose level but partially reduced blood pressure in TGR. Although food consumption was substantially higher in empagliflozin-treated TGR compared to the untreated animals, their body weight and the amount of epididymal and perirenal fat was decreased. Empagliflozin had no effect on proteinuria, but it decreased plasma urea, attenuated renal oxidative stress and temporarily increased urinary urea excretion. Several metabolic (hepatic triglycerides, non-esterified fatty acids, insulin) and inflammatory (TNF-α, leptin) parameters were also improved by empagliflozin treatment. By contrast, echocardiography did not reveal any effect of empagliflozin on cardiac function. In conclusion, empagliflozin exerted beneficial antihypertensive, anti-inflammatory and metabolic effects also in a non-diabetic hypertensive model.
- 650 _2
- $a adipozita $x účinky léků $7 D050154
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antiflogistika $x farmakologie $7 D000893
- 650 _2
- $a antihypertenziva $x farmakologie $7 D000959
- 650 _2
- $a antioxidancia $x farmakologie $7 D000975
- 650 _2
- $a benzhydrylové sloučeniny $x farmakologie $7 D001559
- 650 _2
- $a krevní tlak $x účinky léků $7 D001794
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a energetický metabolismus $x účinky léků $7 D004734
- 650 _2
- $a glukosidy $x farmakologie $7 D005960
- 650 _2
- $a hypertenze $x farmakoterapie $x genetika $x metabolismus $x patofyziologie $7 D006973
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a potkani Sprague-Dawley $7 D017207
- 650 _2
- $a potkani transgenní $7 D055647
- 650 _2
- $a renin $x genetika $7 D012083
- 650 _2
- $a hmotnostní úbytek $x účinky léků $7 D015431
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rauchová, Hana $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Malínská, Hana $u Department of Cardio-Metabolic Research, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Marková, Irena $u Department of Cardio-Metabolic Research, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Hüttl, Martina $u Department of Cardio-Metabolic Research, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Papoušek, František $u Department of Cardiology, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Behuliak, Michal $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Miklánková, Denisa $u Department of Cardio-Metabolic Research, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Vaňourková, Zdeňka $u Department of Experimental Hypertension, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Neckář, Jan $u Department of Cardiology, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Kadlecová, Michaela $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Kujal, Petr $u Department of Pathology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Zicha, Josef $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Vaněčková, Ivana $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic. Electronic address: ivana.vaneckova@fgu.cas.cz
- 773 0_
- $w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 144, č. - (2021), s. 112246
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34601191 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130232 $b ABA008
- 999 __
- $a ok $b bmc $g 1789394 $s 1162972
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 144 $c - $d 112246 $e 20211001 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
- LZP __
- $a Pubmed-20220425
